Argenx’s Vyvgart tops Trinity’s latest launch success analysis, beating out several Big Pharma debuts

Fierce Pharma  |  March 12, 2025

The Trinity Annual Drug Index was featured in an article by Fierce Pharma:

Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, according to the latest edition of Trinity Life Sciences’ annual Drug Index—a trio of factors that explain how argenx’s Vyvgart beat out dozens of other drugs and biologics approved by the FDA in 2021 to be named that year’s strongest launch.